GLOBAL immunology company Argenx has announced that Vyvgart (efgartigimod alfa and hyaluronidase) pre-filled syringe has been approved by the Therapeutic Goods Administration for the treatment of adult patients with generalised myasthenia gravis (gMG).
Already available as an intravenous infusion, the pre-filled syringe offers the convenience of self administration, or it can be administered by a caregiver or healthcare professional.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Mar 26
